The UK’s National Institute for Health and Care Excellence (NICE) has issued further draft guidance reaffirming its decision ...

Despite reporting positive Phase II results for its lead candidate last year, Vaccinex will soon no longer be a publicly ...

US-based Eli Lilly's Kisunla drug and Japanese company Eisai's Leqembi (below), two breakthrough drugs for the diagnosis and ...

Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that have stood in the way of approvals and reimbursement decisions for ...

It's hard to trust the disease statistics when cognitive tests often are not completed, write Robert Brownell and Dr. Yogesh ...

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early symptomatic Alzheimer's disease, a secondary analysis of trial data showed.

Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...

Perhaps Eli Lilly's most promising recent approval is Kisunla, an Alzheimer's disease treatment. Despite an aging population, few medicines in this field have earned the green light from ...